Tilisolol hydrochloride

A &beta-adrenergic receptor agonist with potent positive inotropic effects in vivo strongest effects on &beta1 receptors, with lesser but significant &beta2 receptor activation and only weak &alpha1 receptor actions strongly increases cardiac

Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.In VitroMedroxalol (0.1-10 μM: 20 min) shows α- and β-adrenergic receptor

Medroxalol (RMI81968) is an orally active adrenergic receptor antagonist, blocks α- and β-adrenergic receptors. Medroxalol shows antihypertensive and vasodilating effects.In VitroMedroxalol (0.1-10 μM: 20 min) shows α- and β-adrenergic receptor

Protects the heart from transient ischemia inhibits late sodium and potassium currents (IC₅₀s = 3.9-16.

Protects the heart from transient ischemia inhibits late sodium and potassium currents (IC₅₀s = 3.9-16.

Protects the heart from transient ischemia inhibits late sodium and potassium currents (IC₅₀s = 3.9-16.

Protects the heart from transient ischemia inhibits late sodium and potassium currents (IC₅₀s = 3.9-16.

Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial